Abstract
Simple SummaryDifferent types of breast cancer are typically classified based upon expression of estrogen receptor, progesterone receptor, and epidermal growth factor receptor. One aggressive form of breast cancer is called triple-negative breast cancer (TNBC) because it lacks expression of these proteins. However, TNBC is also heterogeneous and can be further divided into distinct classes including an epithelial-like group and a mesenchymal-like group. The mesenchymal subtype may be vulnerable to therapeutic strategies that oxidize lipids and proteins. The aim of our study was to determine if silver nanoparticles (AgNPs) can cause these types of damage to selectively kill mesenchymal TNBCs. We found that AgNPs killed mesenchymal TNBCs by a mechanism involving lipid and protein oxidation without causing similar toxicity to normal breast cells. This study shows AgNPs are a specific treatment for mesenchymal TNBCs and indicates that stratification of TNBC subtypes may lead to improved outcomes for other therapeutics with similar mechanisms of action.Molecular profiling of tumors shows that triple-negative breast cancer (TNBC) can be stratified into mesenchymal (claudin-low breast cancer; CLBC) and epithelial subtypes (basal-like breast cancer; BLBC). Subtypes differ in underlying genetics and in response to therapeutics. Several reports indicate that therapeutic strategies that induce lipid peroxidation or proteotoxicity may be particularly effective for various cancers with a mesenchymal phenotype such as CLBC, for which no specific treatment regimens exist and outcomes are poor. We hypothesized that silver nanoparticles (AgNPs) can induce proteotoxic stress and cause lipid peroxidation to a greater extent in CLBC than in BLBC. We found that AgNPs were lethal to CLBCs at doses that had little effect on BLBCs and were non-toxic to normal breast epithelial cells. Analysis of mRNA profiles indicated that sensitivity to AgNPs correlated with expression of multiple CLBC-associated genes. There was no correlation between sensitivity to AgNPs and sensitivity to silver cations, uptake of AgNPs, or proliferation rate, indicating that there are other molecular factors driving sensitivity to AgNPs. Mechanistically, we found that the differences in sensitivity of CLBC and BLBC cells to AgNPs were driven by peroxidation of lipids, protein oxidation and aggregation, and subsequent proteotoxic stress and apoptotic signaling, which were induced in AgNP-treated CLBC cells, but not in BLBC cells. This study shows AgNPs are a specific treatment for CLBC and indicates that stratification of TNBC subtypes may lead to improved outcomes for other therapeutics with similar mechanisms of action.
Highlights
Breast cancer is a heterogeneous disease consisting of multiple subtypes
To determine if sensitivity of triple-negative breast cancer (TNBC) cells to AgNPs differed based upon intrinsic subtype, a panel of basal-like breast cancer (BLBC) (HCC70, BT-20, MDA-MB-468) and claudin-low breast cancer (CLBC) (BT-549, MDA-MB-231, MDA-MB-436, SUM159) cell lines were treated with increasing doses of AgNPs
IC50 values of CLBCs ranged from 0.7–18 μg/mL, BLBCs ranged from 48–98 μg/mL, and non-cancer cell lines ranged from 110–346 μg/mL
Summary
Based upon differences in global mRNA expression, TNBC subdivides into distinct, intrinsic molecular subtypes, defined by Perou and colleagues, as claudin-low breast cancer (CLBC) and basal-like breast cancer (BLBC) [2]. CLBC/M and BLBC/BL1/BL2 differ on the molecular level, and in incidence, treatment response, and patient survival [2,3,7,8,9] Despite this heterogeneity, TNBC is treated as a single disease, with standard of care consisting of a combination of chemotherapy, radiation, and surgery
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
